Last reviewed · How we verify
sPLA2 Inhibitor
At a glance
| Generic name | sPLA2 Inhibitor |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase IIb Study to Determine the Efficacy and Safety of the Study Drug in Patients With Severe Sepsis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sPLA2 Inhibitor CI brief — competitive landscape report
- sPLA2 Inhibitor updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI